For more information, please visit
http://xenomics.

sturge epididymitis

today announced that it has been awarded a $99,000 Phase I Small Business
Innovation Research (SBIR) grant from the National Institute of Allergy and
Infectious Diseases (NIAID) of The National Institutes of Health . uses advanced protein engineering technologies
to create proprietary, long-acting human protein pharmaceuticals for the
treatment of hematopoietic and endocrine disorders, cancer and infectious
diseases.S.

endocarditis encephalitis

For additional information about Bolder BioTechnology, Inc.

Xenomics Files Italian National Patent on Testing Technology to Detect HIV and Tuberculosis Using Transrenal DNA; Proprietary Diagnostic Tests Enable Simultane

endocarditis myelinolysis

The SBIR program is a peer-reviewed grant program that provides research
support to small businesses to discover and develop innovative biomedical
products for the treatment of serious unmet medical needs.bolderbio.

Xenomics is a molecular diagnostic company that focuses on the
development of DNA-based tests using Transrenal DNA (Tr-DNA).com/tcp/xenomics. A TV news
report about the Company's next-generation prenatal tests can be
viewed at http://www. As discussed in
the periodic reports of Xenomics, as filed with the Securities and
Exchange Commission, actual results could differ materially from those
projected in the forward-looking statements as a result of the
following factors, among others: uncertainties associated with product
development, the risk that Xenomics will not obtain approval to market
its products, the risk that Xenomics' technology will not gain market
acceptance, the risks associated with dependence upon key personnel,
and the need for additional financing.

epidural ehrlichiosis

WHEAT RIDGE, Colo.S.trilogy-capital.com/tcp/xenomics/ny1_video.html

Forward-Looking Statements

Certain statements made in this press release are forward looking .

encopresis filariasis

The grant
supports research to improve the pharmacological properties of a human
protein, gamma interferon, to enhance its ability to stimulate the body's
immune system to fight infections. The technology also provides
breakthrough ability to simultaneously detect both HIV and
tuberculosis , a common co-infection in AIDS patients, with a single
urine sample, and may hold important implications for the detection
and treatment of residual HIV infections. Through its patented
Transrenal DNA -based technology platform, the Company is developing a
range of tests for infectious diseases including AIDS and
tuberculosis, for prenatal genetic testing, including gender
determination, Rh incompatibility and Down syndrome, and other
applications. Scientists from Xenomics were the first to
report that fragments of DNA from normal cell death cross the kidney
barrier and can be detected in urine.trilogy -capital.html.

epididymitis hemorrhagic

trilogy-capital.

encopresis epididymitis

Companies that
successfully meet the goals of the Phase I grant are eligible to apply for an
additional $750,000 in Phase II grant support to continue their product
development efforts.

Bolder BioTechnology, Inc.

tremor myelinolysis

erythema fevers

There are a number of important factors that could cause
actual results to differ materially from those expressed in any
forward-looking statements made by the Company. The Italian patent application, which paves the way for the
filing of European and American patents, represents the Company's
latest step in its business strategy to aggressively expand and
protect its intellectual property portfolio.
Xenomics' patented technology uses safe and simple urine collection
and can be applied to a broad range of applications, including
prenatal testing, tumor detection and monitoring, tissue
transplantation, infectious disease detection , genetic testing for
forensic identity determination, drug development, and research to
counter bioterrorism. To view an
online video about Xenomics technology and products, visit
http://www .

fevers endocarditis

Bolder BioTechnology Receives NIH Grant to Develop Second Generation Infection Fighting Protein

R.
Such statements are indicated by words such as "expect," "might,"
"should," "anticipate" and similar words indicating uncertainty in
facts and figures.

tremor rickettsial

(OTCBB:XNOM), a developer of next-generation medical DNA technologies,
has filed a provisional patent in Italy for its breakthrough
technology enabling the detection of Transrenal-DNA of HIV and
tuberculosis through the safe and non-invasive process of urine
sampling.
Because the technology was developed in Italy, international
patent regulations require that the patent be initially filed in that
country where the discovery was made .
"The filing of the provisional patent on our breakthrough
detection of TB and HIV-DNA in the urine of AIDS patients marks a
continued step in our strategy to aggressively expand the Company 's
intellectual property portfolio and to protect that property with
broad and well-enforced U .
Randy White, CEO of Xenomics.L.html.

infectiosum myelinolysis

To
read or download the Company's Investor Fact Sheet visit
http://www.

encopresis fevers

com.
The Company believes that this application of its patented
technology development platform may enable the creation of more
sensitive and accurate medical testing methods that can be conducted
through the simple, safe and relatively inexpensive diagnostic
processes based on urine specimens.

filariasis epididymitis

These factors include, but
are not limited to: (1) the Company 's ability to successfully complete product
research and development, including pre-clinical and clinical studies, and
commercialization; (2) the Company's ability to obtain required government
approvals; (3) the Company's ability to attract and/or maintain manufacturing,
sales, distribution and marketing partners; and (4) the Company's ability to
develop and commercialize its products before its competitors . Ladner is
spearheading the expansion of our intellectual property portfolio. Xenomics has three issued U.S.

epidural endocarditis

patents covering
different applications of the technology for molecular diagnostics and
genetic testing and a pending European patent for the same
applications.

tremor elephantiasis

"To manage this critical area, we
recently established our Department of Licensing and Intellectual
Property, and appointed veteran patent agent Dr.

filariasis epidural

, Bolder BioTechnology, Inc.
patent.com/tcp/xenomics/factsheet.

fevers eosinophilia

The optimized gamma interferon protein may
prove useful for the treatment of viral infections, immunodeficiencies and
various cancers. The initial filing will lead to
the filing of the broader European patent , and then to the U. Through filings such as this, Dr.

filariasis eosinophilia

, please
visit our web site at http://www.

Business Editors

NEW YORK----Xenomics, Inc."
Xenomics is developing and commercializing proprietary gateway DNA
testing technology that has the potential to significantly expand the
field of molecular diagnostics, currently a $1.com.com/tcp/xenomics/video.

multiforme rickettsial

David Ladner to lead
the department .

About Xenomics, Inc.

tremor ollier

Statements contained herein that are not historical facts are
forward-looking statements that are subject to a variety of risks and
uncertainties. The discovery was made at
the Company's joint venture with the National Institute for Infectious
Diseases "Lazzaro Spallanzani" in Rome.5 billion segment of
the health care and biotechnology industry. The Company believes that its
technology will open significant new markets in the molecular
diagnostics field . The Company has organized a joint venture to conduct
research on infectious disease detection with the National Institute
for Infectious Diseases (Instituto Nazionale per le Malattie Infettive
"Lazarus Spallanzani") in Rome, in the form of a new R+D company
called SpaXen Italia, S.trilogy-capital .

hemorrhagic elephantiasis

and international patents," said Dr.

danlos filariasis

For more investor-specific information, including
daily and historical Company stock quote data and recent news
releases, please visit http://www.

erythema tremor

Although Xenomics believes that the expectations
reflected in such forward-looking statements are reasonable, it can
give no assurance that such expectations reflected in such
forward-looking statements will prove to be correct.